ALK and non-small cell lung carcinoma: The landmark Checkmate-816 trial randomized 358 stage IB-IIIA resectable NSCLC patients with an ECOG-PS (Eastern Cooperative Oncology Group-Performance Status) of 0–1 and no known ALK or EGFR mutations to receive three cycles of nivolumab plus platinum-based chemotherapy or chemotherapy alone in the neoadjuvant setting [35].